Research graph
References from Association of CYP2C19 genetic polymorphisms with dyslipidemia and ischemic cerebrovascular disease in the mongolian population. Local targets link to admitted publications; unresolved targets remain external evidence.
Effect of CYP2C19 genotype on outcomes of treatment with ticagrelor versus clopidogrel in acute coronary syndrome patients with diabetes mellitus: a analysis in a large-scale, real-world study.
10.1016/j.ejphar.2025.177546 · 2025 · External reference
A 5-decade analysis of incidence trends of ischemic stroke after transient ischemic attack: a systematic review and meta-analysis.
10.1001/jamaneurol.2020.3627 · 2021 · External reference
Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in HighRisk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials.
10.1001/jamaneurol.2019.2531 · 2019 · External reference
The correlation between platelet responsiveness to clopidogrel and CYP2C19 polymorphism in patients with peripheral vascular disease.
2021 · External reference
Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA stratified by age and renal function: CHANCE-2 trial substudy.
10.1080/0886022x.2025.2526684 · 2025 · External reference
CYP2C19 gene profiling as a tool for personalized stress ulcer prophylaxis with proton pump inhibitors in critically ill patients - recommendations proposal.
10.3389/fmed.2022.854280 · 2022 · External reference
Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.
10.1038/s41598-021-02628-x · 2021 · External reference
Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.
10.1007/s00228-020-03050-4 · 2021 · External reference
Phenotyping of human CYP450 enzymes by endobiotics: current knowledge and methodological approaches.
10.1007/s40262-019-00783-z · 2019 · External reference
Genetic polymorphisms of CYP2C19 in ecuadorian population: an interethnic approach.
10.1016/j.heliyon.2024.e28566 · 2024 · External reference
Prevalence of aspirin and clopidogrel resistance in patients with recurrent ischaemic cerebrovascular disease.
10.15420/ecr.2021.16.po16 · 2021 · External reference
PharmVar GeneFocus: CYP2C19.
10.1002/cpt.1973 · 2021 · External reference
Safety of eptifibatide in addition to ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
2025 · External reference
Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine.
10.3390/jpm8010008 · 2018 · External reference
Outcomes of ticagrelor versus high-dose clopidogrel in CYP2C19 intermediate metabolizer undergoing percutaneous coronary intervention for acute coronary syndromes.
10.1097/fjc.0000000000001582 · 2024 · External reference
CYP2C gene polymorphisms in North African populations.
10.1007/s11033-024-10093-8 · 2024 · External reference
Characteristics and predictors of cardiovascular events related to CYP2C19 gene polymorphisms following acute coronary syndrome.
2024 · External reference
Association between CYP2C19 gene polymorphisms and lipid metabolism in Chinese patients with ischemic stroke.
10.1177/0300060520934657 · 2020 · External reference
Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in cpatients at high cardiovascular risk: the STRENGTH randomized clinical trial.
10.1001/jama.2020.22258 · 2020 · External reference
Triglyceride lowering with pemafibrate to reduce cardiovascular risk.
10.1056/nejmoa2210645 · 2022 · External reference
Remnant cholesterol and risk of myocardial infarction in patients with coronary artery disease undergoing revascularization.
10.1016/j.jacl.2023.03.009 · 2023 · External reference
Dual antiplatelet therapy with ticagrelor vs clopidogrel in patients with TIA or minor stroke with or without symptomatic carotid artery stenosis: a post hoc analysis of the CHANCE-2 trial.
10.1136/svn-2024-003293 · 2025 · External reference
